Xiaoli He

Dr. Xiaoli He


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 January 2020 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
XHXiaoli He
Xiaoli He
YHYan-Ming He
Yan-Ming He
DZDan Zhang
Dan Zhang
HLHong-Shan Li
Hong-Shan Li
QZQiang Zhang
Qiang Zhang
PZPing Zhou
Ping Zhou
Yueju, a famous classic Chinese prescription, has been extensively used in treating depression syndromes for hundreds of years. Recent studies have reported that Yueju showed good effects in treating metabolic diseases, such as obesity and hyperlipidemia. Nonalcoholic steatohepatitis (NASH), which leads to cirrhosis and severe cardiovascular diseases, is closely linked to obesity and abnormal lipid metabolism. In this study, Yueju could decrease the levels of alanine aminotransferase, aspartate transaminase, triglyceride, cholesterol, and low‐density lipoprotein‐C but increase the high‐density lipoprotein‐C in the serum of the NASH rat model induced by high‐fat and high‐cholesterol diet. Yueju could alleviate hepatosteatosis by increasing the phosphorylation of acetyl‐CoA carboxylase and inhibiting the expression of fatty acid synthase and stearoyl‐CoA desaturase 1. Yueju downregulated the expression of α‐smooth muscle actin and collagen type 1A1, ameliorating the liver fibrilization. Yueju could also protect the hepatocytes from apoptosis by upregulating antiapoptosis protein Bcl‐2 and X‐linked inhibitor of apoptosis protein and downregulating apoptotic proteins Bax and cleaved poly ADP‐ribose polymerase. Thus, Yueju could improve liver function, regulate lipid metabolism, alleviate hepatosteatosis and fibrosis, and protect hepatocytes from apoptosis against NASH. Yueju may be used as an alternative effective medicine for NASH treatment.

18 April 2022
Verified
Conference Paper
Closed access
XHXiaoli He
Xiaoli He
YDYuchen Du
Yuchen Du
JPJianwei Peng
Jianwei Peng
HYHong Yu
Hong Yu
SSSangameshwar Rao Saudari
Sangameshwar Rao Saudari
OHOwen Hu
Owen Hu
Single diffusion break (SDB) devices in FinFET technology are desirable and attractive for their minimum footage in aggressively scaled circuits. This paper reports fin-shape optimization efficiently improved SDB PFET device performance by up to 9%. More importantly, it was found that the performance benefit was case-dependent on fin shape. The performance improvement was observed on a straighter fin profile if fin bottom width was lower than a threshold point, while when fin bottom width was larger than the threshold point, fin top/bottom width ratio existed an optimal ratio at 0.54. This was verified and predicted through silicon-validated technology computer-aided design (TCAD) simulation.

11 July 2023 in Heliyon
Verified
Journal Article
Open access
PLPing-Lan Lin
Ping-Lan Lin
TWTao-Tao Weng
Tao-Tao Weng
LDLian-Xiang Duan
Lian-Xiang Duan
LZLin-Zhang Zhang
Lin-Zhang Zhang
XWXia Wei
Xia Wei
JHJing Hu
Jing Hu
Renal fibrosis (RF) is a common pathological feature of chronic kidney disease (CKD), which remains a major public health problem. As now, there is still lack of chemical or biological drugs to reverse RF. Shen-shuai-yi Recipe (SSYR) is a classical Chinese herbal formula for the treatment of CKD. However, the effects and mechanisms of SSYR in treating RF are still not clear. In this study, the active constituents SSYR for treating RF were explored by UHPLC-Q-Orbitrap HRMS. Bioinformatics analyses were employed to analyze the key pharmacological targets and the core active constituents of SSYR in the treatment of RF. In experimental validation, vehicle or SSYR at doses of 2.12 g/kg/d and 4.25 g/kg/d were given by orally to unilateral ureteric obstruction (UUO) mice. 13 days after treatment, we detected the severity of renal fibrosis, extracellular collagen deposition and pre-fibrotic signaling pathways. Bioinformatics analysis suggested that signal transducer and activator of transcription 3 (STAT3) was the core target and lenticin, luteolin-7-O-rutinoside, hesperidin, kaempferol-3-O-rutinoside, and 3,5,6,7,8,3′,4′-heptamethoxyflavone were the key constituents in SSYR for treating RF. SSYR significantly reduced the expressions of fibronectin (FN), α-smooth muscle actin (α-SMA), collagen-I and alleviated renal interstitial collagen deposition in UUO kidneys. In mechanism, SSYR potently blocked the phosphorylation of STAT3 and Smad3 and suppressed the expression of connective tissue growth factor (CTGF). Collectively, SSYR can ameliorate RF via inhibiting the phosphorylation of STAT3 and its downstream and reducing the collagen deposition, suggesting that SSYR can be developed as a novel medicine for treating RF.

6 May 2023 in Medicina
Verified
Journal Article
Open access
PDF file
BLBo Lu
Bo Lu
WSWenli Shi
Wenli Shi
XZXunjie Zhou
Xunjie Zhou
DFDeyu Fu
Deyu Fu
LDLei Duan
Lei Duan
XZXinyue Zhang
Xinyue Zhang
Background and Objectives: The aim was to explore the interventional effect of the traditional Chinese medicine (TCM) exercise of Tian Dan Shugan Tiaoxi on the emotions of patients with mild novel coronavirus (COVID-19). Materials and Methods: A total of 110 asymptomatic and mildly symptomatic COVID-19 patients from Hongkou Memorial Road Temporary Cabin Hospital and South Renji Hospital were selected between April 2022 and June 2022, and randomly divided into two groups: a control group and an intervention group. There were 55 participants in each group. The control group was treated with Lianhua Qingwen granules, and members of the intervention group were made to practice Tian Dan Shugan Tiaoxi (an exercise that soothes the liver and regulates emotions) every day for 5 days. The Patient Health Questionnaire-9 (PHQ-9), the Generalized Anxiety Disorder questionnaire (GAD-7), and the Symptom Checklist 90 (SCL-90) were used to evaluate the data collected before and after the trial. Results: The incidence of anxiety and depression was high in the patients included in this study, at 73.64% and 69.09%, respectively. After intervention, the scores of the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder questionnaire (GAD-7) in the two groups had decreased in comparison with those recorded before intervention (p < 0.05). The PHQ-9 and GAD-7 scores in the intervention group were significantly better than those of the control group (p < 0.05). The factors of somatization, depression, anxiety, hostility, and fear in the SCL-90 in the intervention group were significantly improved after intervention, and generally, better than those in the control group (p < 0.05). Conclusions: Patients infected with novel coronavirus in shelter hospitals have different degrees of emotional abnormalities. Tian Dan Shugan Tiaoxi can reduce the anxiety and depression of people with mild novel coronavirus, and it can be practiced clinically to improve the recovery rate among infected people.

9 March 2026 in Pharmaceutical Biology
Verified
Journal Article
Open access
XFXinyi Fu
Xinyi Fu
JYJiawen You
Jiawen You
YYYunyi Yang
Yunyi Yang
SQShenglan Qi
Shenglan Qi
SYShiyu Yang
Shiyu Yang
YHYanming He
Yanming He
Agrimonia pilosa Ledeb. (AP), a traditional herbal medicine rich in flavonoids, phenolics, triterpenoids, and glycosides, has been widely used for hepatic injury and metabolic disorders. This study integrated in vivo and in vitro experiments, UHPLC-HRMS profiling, network pharmacology, and molecular simulation to elucidate the bioactive constituents and mechanisms of AP against metabolic dysfunction-associated steatohepatitis (MASH). Therapeutic efficacy was evaluated using a MASH mouse model, AML12 hepatocytes, and RAW264.7 macrophages. Active constituents were identified by UHPLC-HRMS, and potential targets were predicted via SwissTargetPrediction and GEO databases, followed by PPI network construction, GO/KEGG enrichment analysis, molecular docking, and molecular dynamics simulation. AP markedly reduced body weight, liver index, and serum AST, ALT, TG, TC, and LDL-c levels, and attenuated hepatic steatosis, inflammation, and fibrosis. In AML12 cells, AP suppressed lipogenesis by downregulating SREBP-1c, FASN, and SCD1, while promoting fatty acid β-oxidation through CPT1A upregulation. In RAW264.7 macrophages, AP inhibited LPS-induced expression of TNF-α, IL-1β, and IL-6. A total of 83 active constituents and 25 key targets were identified, with HMGCR and AXL emerging as hub nodes. Agrimol B (AGB) exhibited favorable binding affinity and structural stability toward both targets. Mechanistically, AGB inhibited HMGCR, reduced SREBP-2 nuclear translocation, and enhanced LXRα/β-mediated cholesterol efflux, maintaining hepatic cholesterol homeostasis. These findings demonstrate that AP ameliorates MASH through coordinated regulation of lipid metabolism, inflammatory suppression, and collagen deposition, with AGB representing a promising bioactive candidate warranting further investigation.